Prognostic significance of pretreatment systemic immune-inflammation index in patients with prostate cancer: a meta-analysis.

For the PCa sufferers, the SII might be a promising prognostic biomarker, which is applicable to the high-risk subgroup identification, and provide personalized therapeutic strategies.